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ment resulted in increased or decreased levels of sev-
eral mRNAs, including transcription factors (c-fos, hsf-1, 
egr-1) and cell cycle-associated genes (Cdk2, cyclin D1). 
In an attempt to verify the cDNA array results and be-
cause egr-1 was recently implied in Leydig cell develop-
ment, we further studied this factor. RT-PCR and Western 
blotting confi rmed a time-dependent regulation of egr-1 
in TM3. In the postnatal testis egr-1 was seen in cytoplas-
mic and nuclear locations of developing Leydig cells, 
which bear GABA A  receptors and correspond well to 
TM3 cells. Thus, GABA acts via an untypical novel signal-
ling pathway in TM3 cells. Further details of this pathway 
remain to be elucidated. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The neurotransmitter   -aminobutyric acid (GABA) 
exerts its actions via the ionotropic GABA A  and GABA C  
receptors, as well as via the metabotropic GABA B  recep-
tor. The GABA A  and GABA C  receptors are pentameric 
Cl –  channels, which are formed from different subunits 
(GABA A  receptor:   1-6,   1-4,   1-4,   ,   ,   ; GABA C  re-
ceptor:   1-3). GABA B  receptors are G-protein-coupled 
and mediate the GABA signal via several second messen-
ger pathways  [1] . Specifi c pharmacologically defi ned ago-
nists and antagonists exist for each receptor type. 
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 Abstract 
  -Aminobutyric acid (GABA) is an emerging signalling 
molecule in endocrine organs, since it is produced by 
endocrine cells and acts via GABA A  receptors in a para-
crine/autocrine fashion. Testicular Leydig cells are pro-
ducers and targets for GABA. These cells express GABA A  
receptor subunits and in the murine Leydig cell line TM3 
pharmacological activation leads to increased prolifera-
tion. The signalling pathway of GABA in these cells is not 
known in this study. We therefore attempted to elucidate 
details of GABA A  signalling in TM3 and adult mouse Ley-
dig cells using several experimental approaches. TM3 
cells not only express GABA A  receptor subunits, but al-
so bind the GABA agonist [ 3 H]muscimol with a binding 
affi nity in the range reported for other endocrine cells 
(K d  = 2.740  8 0.721 n M ). However, they exhibit a low 
B max  value of 28.08 fmol/mg protein. Typical GABA A  re-
ceptor-associated events, including Cl –  currents, chang-
es in resting membrane potential, intracellular Ca 2+  or 
cAMP, were not measurable with the methods employed 
in TM3 cells, or, as studied in part, in primary mouse 
Leydig cells. GABA or GABA A  agonist isoguvacine treat-
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 GABA and GABA receptors are not only found in the 
central nervous system, but also in peripheral endocrine 
organs, for example in growth hormone (GH) cells of the 
anterior pituitary lobe  [2–4] , in pancreatic islets  [5–7] and 
in the testis of human and rodents  [8, 9] . In these endo-
crine tissues, GABA, in general, is believed to regulate 
synthesis and release of hormones in an auto-/paracrine 
manner. However, we recently identifi ed another GABA-
ergic function in the testis. We found that GABA and a 
GABA A  agonist stimulate proliferation of TM3 cells 
 [10] , a murine cell line of immature Leydig cells  [1, 11] . 
This action appeared to be mediated via a GABA A  recep-
tor, since the effect could be evoked by the GABA A  re-
ceptor agonist isoguvacine and was blocked by bicucul-
line, a GABA A  receptor antagonist. Furthermore, several 
GABA A  subunits were identifi ed by RT-PCR in TM3 
cells. Since in the postnatal testis Leydig cells also express 
GABA A  receptor subunits and possess active GAD (glu-
tamic acid decarboxylase)  [8] , we assume a functional role 
for locally produced GABA in developing Leydig cells. 
 Participation of GABA in migration, proliferation and 
differentiation of cells is known from the central nervous 
system, where GABA acting via GABA A  receptors is in-
volved in neurogenesis during embryonic development 
 [12–17] and in progenitor cell proliferation in different 
regions of the developing brain  [18–22] . Additionally, 
GABA is reported to be involved in neurite outgrowth 
 [23] and migration  [24, 25] of embryonic rat neurons. In 
all those cases, GABA acts as an auto-/paracrine factor as 
GABA synthesis and receptors are located in the same 
cell. The way of action of the GABA A  receptor in imma-
ture neurons, contrary to mature neurons, is associated 
with depolarization of the cell membrane  [14, 26, 27] . 
Despite the fact that there are many reports of non-syn-
aptical GABA effects and actions, little is known about 
the subsequent intracellular pathways, but increased Ca 2+  
levels and altering cAMP levels are two documented pos-
sibilities  [24, 28–32] . 
 Based on our previous results implying GABA A  medi-
ated effects obtained in TM3 Leydig cells, we now aimed 
to identify details of the signalling cascade of GABA in 
TM3 cells focusing on cAMP, Ca 2+ , Cl –  currents, changes 
in membrane potential and regulation of gene expression. 
 Methods 
 Leydig Cells Purifi cation 
 Leydig cells were isolated from a pool of 16 testes obtained from 
8 adult BALB/c mice  (60–90 days of age; Technische Universität 
München). Leydig cells were isolated under sterile conditions using 
a discontinuous Percoll density gradient as previously described  [33] . 
Cells that migrated to the 1.06–1.12 g/ml density fraction were col-
lected and suspended in Medium 199, yielding an 85–90% enriched 
Leydig cell fraction. An aliquot was incubated for 5 min with 0.4% 
Trypan blue and used for cell counting and viability assay in a light 
microscope. Viability of Leydig cell preparations was 98–99%. 
 Cell Culture 
 Isolated Leydig cells were cultivated in Medium 199 (Sigma-
Aldrich, St. Louis, Mo., USA) at 37  °  C in an atmosphere containing 
95% air and 5% carbon dioxide (vol/vol). TM3 cells were derived 
from immature mouse Leydig cells (d14)  [11, 34] and were cultured 
in F12-DME medium (pH 7.2; Sigma, Deisenhofen, Germany) 
supplemented with 5% horse serum (all from Biochrom AG, Berlin, 
Germany and PAA GmbH, Cölbe, Germany) and 2.5% fetal calf 
serum FCS Gold (PAA). The cells were kept at 37  °  C in a humidi-
fi ed  atmosphere containing air and carbon dioxide (95%/5% vol/
vol). In order to study egr-1 expression, the cell cycles of TM3 cells 
were synchronized by culturing cells for 3 h in serum-reduced me-
dium (1% fetal calf serum, 2.5% horse serum). TM3 cells were in-
cubated subsequently in the same serum-reduced medium with 
10   M GABA, 10   M GABA A  agonist isoguvacine and 10   M 
GABA B  agonist baclofen (Biotrend GmbH, Cologne, Germany) for 
various time points (5, 10, 15, 30, 60 or 90 min). 
 Binding Assay 
 For binding assays, TM3 cells were plated in 24-well plates for 
24 h. Each well contained approximately 5  ! 10 5  cells in 250   l of 
serum-reduced medium (F12-DME, 2.5% horse serum, 1.25% fetal 
calf serum). The following day, cells (approx. 60–70   g protein) 
were washed 3 times with F12-DME medium without serum and 
suspended in Tris-citrate buffer (50 m M , pH 7.1, fi nal volume 
250   l). Saturation binding studies were performed with six con-
centrations of [ 3 H]muscimol (0.75–30 n M ). Non-specifi c binding 
was determined in the presence of 100   M unlabelled GABA. The 
mixture was incubated at 37  °  C under a humid atmosphere of 5% 
CO 2  for 30 min. Incubation was stopped by washing cells with F12-
DME medium without serum. Finally, cells were transferred into 
1.6 ml liquid scintillation cocktail (Optiphase Hisafe 2, Wallac 
Scintillation Products, Wallac Oy, Turku, Finland) for radioactiv-
ity counting. All individual assays were carried out in replicates of 
four. Scatchard plots were drawn by using the computer program 
PRISM (GraphPad, San Diego, Calif., USA). Dissociation constant 
(K d ) was expressed in n M . Maximal binding (B max ) was expressed 
in fmol/10 6  cells and fmol/mg protein. Protein concentration was 
measured using bovine serum albumin as standard. 
 Immunohistochemistry 
 For immunohistochemistry we employed a rabbit polyclonal 
antiserum against egr-1 (diluted 1:  500; Santa Cruz Biotechnology, 
Inc., Santa Cruz, USA). Testicular distribution of egr-1 was exam-
ined in sections (5   m) of paraffi n-embedded testes of d5/6 rodents. 
These tissue blocks have already been used in previous studies  [35] . 
An avidin-biotin-peroxidase immunohistochemical method was 
employed as described previously  [36] . A biotin-coupled polyclonal 
goat anti-rabbit antiserum (diluted 1:  500; Jackson, Inc., West 
Grove, Pa., USA) served as secondary antiserum. Diaminobenzi-
dine was used as a chromogen. Sections incubated with buffer 
alone, buffer containing rabbit non-immune serum and buffer con-
taining egr-1 antiserum, which was preadsorbed with egr-1 blocking 
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peptide (both from Santa Cruz Biotechnology, Inc.), respectively, 
were used as controls. The sections were examined with an Axiovert 
photomicroscope (Zeiss, Oberkochen, Germany). 
 Western Blotting 
 For Western blot analyses we employed rabbit polyclonal anti-
serum against egr-1 (Santa Cruz Biotechnology, Inc.), and mouse 
monoclonal antiserum against   -actin (Sigma). Western blot anal-
yses were performed with minor modifi cations as described previ-
ously  [37] . In brief, TM3 cells were lyzed and homogenized by 
sonication in 62.5 m M Tris-HCl buffer (pH 6.8) containing 10% 
sucrose and 2% SDS, mercaptoethanol was added (10%), and the 
samples were heated (95  °  C for 5 min). Protein content was record-
ed using a Folin phenol quantitation method (DC protein assay, 
BioRad GmbH, München, Germany)  [38] . Then, 15   g protein per 
lane were loaded on Tricine-SDS-polyacrylamide gels (12.5%), 
electrophoretically separated, and blotted onto nitrocellulose. Sam-
ples were probed with antiserum directed specifi cally against egr-1, 
and   -actin (incubation overnight at 4  °  C, dilution 1:  500). Immu-
noreactivity was detected using peroxidase-labelled goat anti-rab-
bit antiserum (diluted: 1:  5,000; Jackson, Inc.) or peroxidase-cou-
pled goat anti-mouse antiserum (diluted: 1:  5,000; Jackson, Inc.) 
and an enhanced chemiluminescence detection kit (Amersham-
 Buchler, Braunschweig, Germany). 
 RNA Preparation and Semiquantitative RT-PCR 
 Isolation of RNA from TM3 cells, as well as RT and PCR for 
egr-1 and cyclophilin A were performed as described  [39] . Condi-
tions of PCR amplifi cation consisted of 35 cycles (94  °  C for 30 s, 
55  °  C for 30 s, 72  °  C for 60 s, followed by fi nal extension for 5 min 
at 72  °  C). Oligonucleotide primers (egr-1: sense 5  -acaagaaagcaga-
caaaagtg-3  , antisense 5  -gtcgctgtcatgtctgaaag-3  ; cyclophilin A: 
sense 5  -tggcaagtccatctacgg-3  , antisense 5  -gagctacagaaggaatgg-3  ) 
were synthesized according to published sequences. Verifi cation of 
cDNAs was achieved by direct sequencing  [40] . 
 cDNA Array Studies 
 We used the mouse pathfi nder 1 GEArray and the GEArray Q 
series mouse signal transduction pathwayfi nder gene arrays (Super-
array, Inc., Bethesda, Md., USA) to analyze the GABA-regulated 
genes in TM3 cells, comparing unstimulated versus GABA (10   M ) 
or isoguvacine (10   M ) treated cells after 60, 90 or 120 min. The ar-
rays were performed following the instructions provided by the man-
ufacturer and as described before  [41] . In brief, array membranes 
were hybridized with biotin-labelled cDNA and after binding of al-
kaline phosphatase-conjugated streptavidin and addition of CDP-
Star solution the chemiluminescence signals of the spotted genes 
were detected by exposing the membranes to x-ray fi lms (Hyperfi lm, 
Amersham Pharmacia Biotech, Little Chalfont, Bucks., UK). Digi-
tized images were evaluated as illustrated previously  [41] . 
 Electrophysiological Recordings 
 Cells were perfused with an ‘extracellular’ medium containing 
140 m M NaCl, 2.7 m M KCl, 1 m M MgCl 2 , 1.5 m M CaCl 2 , 6 m M 
glucose and 12 m M Hepes, pH was adjusted to 7.3. The medium 
was exchanged continuously at about 4.5 ml/min. The membrane 
conductance of the cells was determined at room temperature (23–
25  °  C) by using the whole-cell recording mode of the patch-clamp 
technique. The equipment consisted of an EPC-9 patch-clamp am-
plifi er and TIDA software as provided by HEKA (Lambrecht, Ger-
many). The patch pipettes were drawn from borosilicate glass with 
a pipette resistance of 3–6 M 	 and fi lled with an ‘intracellular’ me-
dium containing 140 m M KCl, 2 m M Na 2 ATP, 2 m M MgCl 2 , 
2 m M EGTA, 10 m M Hepes, and pH was adjusted to 7.2. In order 
to improve sealing, the pipette was briefl y dipped into 2% dimeth-
yldichlorosilane, dissolved in methylene chloride. Membrane
currents were recorded with membrane potential clamped to 
–80 mV. 
 Fluorescence Measurements 
 (a) Ca 2+  measurements were performed as described  [42] . Brief-
ly, the cells were loaded with Fura-2/AM (2.5   M , dissolved in 
DMSO) for 30 min at 37  °  C in a standard external solution, consist-
ing of 140 m M NaCl, 2.7 m M KCl, 1.5 m M CaCl 2 , 1 m M MgCl 2 , 
6 m M glucose, 12 m M HEPES, pH adjusted to 7.3. Before measure-
ments, cells were extensively rinsed with the dye-free solution. Flu-
orescence measurements were performed with the Zeiss Fast Fluo-
rescence Photometry System (MPM-FFP, Zeiss) which is based on 
an inverted microscope (Axiovert 35), equipped for epifl uores-
cence. The excitation wavelength was switched, at 400 Hz, between 
340 and 380 nm using appropriate interference fi lters (bandwidth 
10 nm) mounted alternatingly in a fi lter wheel. This system allows 
one to monitor the emitted light (505–530 nm) with a time resolu-
tion of 5 ms for one pair of excitation wavelengths. The recorded 
data were averaged to achieve a fi nal time resolution of 80 ms. Ca 2+  
levels are given in the fi gures as fl uorescence ratios obtained from 
alternating excitation at 340 and 380 nm. 
 (b) The resting membrane potential (V R ) was monitored using 
the fl uorescent potential probe DiBAC 4 (3) (Molecular Probes, Eu-
gene, Oreg., USA) which distributes over the plasma membrane 
dependent on V R . DiBAC 4 (3) is one of the most sensitive potential 
probes available (1% fl uorescence change per mV), but reacts rath-
er slow (about 30–60 s). Real-time intracellular DiBAC 4 (3) fl uores-
cence was imaged in a recording chamber mounted on a TCS SP2 
confocal microscope (Leica Microsystems, Heidelberg, Germany). 
The potential probe was excited at 488 nm, fl uorescence was de-
tected in the range from 500 to 540 nm and the intracellular signal 
intensity was quantifi ed. Cells were preincubated with 1   M Di-
BAC 4 (3) containing extracellular solution (140 m M NaCl, 3 m M 
KCl, 1 m M CaCl 2 , 10 m M Hepes, 10 m M glucose, pH 7.4) for 
10 min. Then, GABA (100   M ) dissolved in the DiBAC 4 (3) solu-
tion was applied for up to 10 min by a fi ne steel needle placed in 
close proximity to the cells. 
 Drug Application for Electrophysiological Recordings and Ca 2+  
Measurements 
 Agents were applied to the cells using the L/M-SPS-8 superfu-
sion system (List, Darmstadt, Germany). To restrict the presence 
of the agent to a small volume within the Petri dish, a combination 
of two perfusion systems was installed, i.e. (i) a global bath perfu-
sion with the infl ow set at 4.5 ml/min and an outfl ow which re-
moved any excess fl uid, and (ii) a local bath perfusion that gener-
ated a continuous fl uid stream containing the agent in the desired 
concentration. The local inlet (tip of an eight-barrelled pipette) was 
positioned at a distance of 50–100   m upstream and the local out-
let at about 300   m downstream of the measuring fi eld. Drugs were 
administered by a combination of gravity and an additional pres-
sure control system which resulted in a fl ow rate of about 1 ml/min. 
The selection among the 8 syringes connected to the eight-barrelled 
pipette was controlled with magnetic valves. 
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 cAMP Assay 
 Measurements of cAMP levels were performed using TM3 cells 
either untreated or treated with GABA (10   M ) employing a com-
mercially available kit (Cayman Chemical, Ann Arbor, Mich., USA). 
After different incubation times, samples (supernatants and cell pel-
lets) were frozen and stored at –80 °  C until analysis. The logarithmic 
standard curve was linear between 2.3 and 300 pmol/ml. 
 Results 
 Muscimol Binding Assay 
 Scatchard analysis of [ 3 H]muscimol binding to TM3 
cells yielded a linear plot with a dissociation constant (K d ) 
of 2.740  8 0.721 n M and maximal binding (B max ) of 
3.501  8 0.595 fmol/10 6  cells or 28.080  8 4.774 fmol/mg 
protein (means  8 SEM). The results obtained are consis-
tent with a single homogeneous population of binding 
sites ( fi g. 1 ). 
 GABA and the GABA A  Agonist Isoguvacine Increase 
the mRNA and Protein Levels of egr-1 in TM3 Cells 
 cDNA array studies were performed with TM3 cells 
treated with GABA and with the GABA A  receptor agonist 
isoguvacine for 60, 90 and 120 min. GABA (10   M ) and 
isoguvacine (10   M ) increased the levels of several 
mRNAs, including transcription factors, such as c-fos on-
cogene (c-fos,  fi g. 2 a), heat shock factor 1 (hsf-1;  fi g. 2 a) 
and early growth response factor 1 (egr-1;  fi g. 2 b) and de-
 Fig. 1. Scatchard plot of [ 3 H]muscimol binding to TM3 cells. Re-
sults of muscimol binding to TM3 cells (one of two experiments 
yielding almost identical results) is shown and results are expressed 
per cell number and protein content. 
egr-1
5 10 15 30 90 min
a
egr-1






 Fig. 2. Results from cDNA array studies and RT-PCR.  a Example 
result from cDNA array studies showing that c-fos (boxed) and heat 
shock factor (hsf-1; circled) mRNA levels are increased 2- to 3-fold 
after 90 min of isoguvacine (ISO) treatment (10   M ; duplicate 
blots). Compare with table 1, in which results after 120 min are 
summarized and imply dynamic regulation of e.g. hsf-1.  b Upper 
panel: Result from cDNA array study showing that egr-1 mRNA 
levels are increased after 60 min of GABA (10   M ) treatment (du-
plicate blots). Lower panel: Semiquantitative RT-PCR showing 
egr-1 mRNA expression levels in TM3 cells from 5 to 90 min after 
10   M GABA treatment (1 representative of 3 independent ex-
periments). Cyclophilin A (cyclo) expression at the same time 
points as control of potential loading differences. 
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creased the mRNA levels of cyclin-dependent kinase 2L 
(cdk2; not shown), all at least 2-fold within 60–90 min. 
Levels of bone mophogenic protein 4 (BMP4), cyclin D1, 
p53, hsf-1, heat shock protein 90 and others were found 
to be decreased after 120 min of treatment with isoguva-
cine ( table 1 ). 
 Because of its known involvement in the processes 
of mitosis and differentiation, we focused on the major 
transcription factor egr-1 and attempted to verify theses 
results at mRNA and at the protein level. We confi rmed 
by RT-PCR studies a GABA-induced up-regulation of 
egr-1 mRNA expression from 10 to 90 min ( fi g. 2 b; 
n = 3 independent experiments) and a similar effect of 
isoguvacine (n = 2 independent experiments; data not 
shown) in TM3 cells. These results are strongly sup-
ported at the protein level by further Western blot 
 experiments, in which egr-1 protein levels were found 
to be increased after GABA and isoguvacine treatment 
in a time-dependent manner ( fi g. 3 ; n = 5 independent 
experiments). 
 Immunolocalization of egr-1 in Testes 
 In order to be able to judge whether egr-1 is present in 
Leydig cells, immunostaining for egr-1 was performed in 
testicular sections of adult and immature (d5–6) rodent 
testes, namely mouse (not shown) and rat. Immunoreac-
tivity of the transcription factor egr-1 was found in cyto-
plasmic as well as in nuclear location in proliferating in-
terstitial Leydig cells at d5–6, but not in Leydig cells of 
adult testes. Immunostaining was specifi c since all con-
trols performed including preadsorption of egr-1 antise-
rum were negative ( fi g. 4 ). 
 Electrophysiological Studies and Analysis of Second 
Messenger Pathways in TM3 Cells and Isolated 
Leydig Cells during GABA Treatment 
 Whole-cell patch-clamp experiments showed that 
acute treatment with GABA (100   M ) did not induce any 
measurable Cl –  currents in TM3 and adult Leydig cells 
( fi g. 5 ; n = 10 cells each). In accordance with this result, 
no measurable change in resting membrane potential of 
TM3 cells was detected using the fl uorescent potential 
probe DiBAC 4 (3) (results not shown). Furthermore, fl uo-
rescence measurements indicated absence of measurable 
GABA (100   M )-mediated alteration in intracellular 
Ca 2+  levels in either cell type (data not shown). A cAMP 
assay performed in TM3 cells, likewise, showed no al-
teration of the cytoplasmic levels of this second messen-
ger 30 min after GABA stimulation (values given as 
means  8 SD: 7.14  8 1.96 pmol/ml;  n = 6) in TM3 cells 
(untreated cells: 7.92  8 1.73 pmol/ml; n = 6) and there-
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Table 1. Isoguvacine treatment (10 M) for 120 min reduced the 
transcript levels of several genes (data from cDNA array; optical 
densities were normalized to -actin levels and expressed as ratio 
of untreated control and treated groups)
Name/Genebank Accession No. Fold reduction
Bone morphogenic protein 4 (NM007554) 2.2
Cyclin-dependent kinase 2L (AJ223732) 2.5
Cyclin D1 (M64403) 1.8
Engrailed homologue 1 (NM010133) 7.0
Glycogen synthase (U53218) 2.8
P53 (K01700) 4.5
Heat shock factor-1 (X61753) 23
Heat shock protein 90 (NM023633) 3.3
Compare fi gure 2 for up-regulated levels after 90 min.
 Fig. 3. Western blot results depicting expression pattern of egr-1 
protein in TM3 cells after GABA/isoguvacine stimulation. Western 
blot experiments showing egr-1 protein levels after 10   M GABA 
( a , n = 3) and 10   M isoguvacine stimulation ( b , n = 2). In order 
to take into account small loading differences, protein levels of   -
actin were also analysed and are shown. 
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 Discussion 
 Recently we provided evidence for testicular GABA 
production, testicular GABA A  receptor subunit expres-
sion and GABA-induced Leydig cell proliferation. There-
fore, we suggested that GABA is involved in development 
of Leydig cells in postnatal testis. Furthermore, based on 
actions of GABA agonists/antagonists on TM3 cells, 
which express GABA A    ,   and   subunits, we concluded 
that GABA A  receptors are responsible for the initial sig-
nal transduction  [8, 10] . 
 In the present study we have attempted to analyze ini-
tial events in GABA action via the presumed GABA A  
receptor. Our results indicate that GABA binds to TM3 
and may act via an unusual pathway, which does not in-
clude obvious changes in membrane potential, Cl –  cur-
rents, changes of cAMP or Ca 2+ , but rather involves reg-
ulation of many genes, as was further verifi ed for the mas-
ter transcription factor egr-1. 
 TM3 Leydig cells are the main model system used for 
our studies, and as previously defi ned, they produce 
GABA, express the GABA A  receptor subunits   1,   2,   1, 
 Fig. 4. Immunohistochemical detection of 
egr-1 in postnatal (day 6) and adult testes. 
 a Immunoreactive egr-1 is detected in nu-
clei of interstitial cells, some of which are 
very likely to represent cells of the adult-
type lineage in the day 6 rat testis. Bar: 
15   m.  b Groups of interstitial cells show 
immunoreactivity in the cytoplasm or in the 
nucleus in the day 6 rat testis. These groups 
most likely represent fetal-type Leydig cells. 
Bar: 15   m.  c Control staining of a day 6 
testis, in which preadsorbed egr-1 antise-
rum was employed, resulting in complete 
absence of staining. Bar: 15   m.  d Staining 
with the egr-1 antiserum in adult testis: In-
terstitial cells including Leydig cells are not 
stained and as expected  [64] staining is 
 restricted to the tubular compartment. Bar: 
40   m.  e Control of an adult testis in which 
preadsorbed egr-1 antiserum was employed. 
Bar: 40   m. 
LC
TM3
100  GABAµM 100 pA
2 s
 Fig. 5. Patch-clamp results of TM3 and 
adult Leydig cells treated with GABA. 
Patch-clamp results showing that GABA 
(100   M ) does not evoke currents in TM3 
(upper line) or in isolated Leydig cells (LC, 
lower line). 
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  3 and   1 and respond to GABA and GABA A  agonist 
treatment by increased proliferation  [10] . TM3 cells thus 
resemble in particular the cells of the Leydig cell lineage 
found in the developing testis  [10] . In some of our studies 
we also used isolated mouse Leydig cells, which, as our 
unpublished RT-PCR results showed, possess   1,   2,   3 
and   3 subunit mRNAs. These results are in line with a 
study examining GABA A  subunit expression in the testis 
and other peripheral organs  [43] . 
 According to current knowledge the observed array of 
receptor subunits expressed by TM3 should be suffi cient 
to assemble in the cell membrane to form a functional 
GABA A  channel  [44–47] . GABA A  receptors are penta-
meric channels and in the brain consist of mainly   1,   2 
and   2 subunits  [48] . However, a multitude of different 
combinations exists due to the fact that multiple other 
subunits can assemble. Importantly it is thought that res-
idues in the   subunit may defi ne high-affi nity agonist 
binding  [49] , while the activation site for GABA is lo-
cated at the   -  interface  [50] . 
 At least in TM3 cells, results from our studies with 
[ 3 H]muscimol binding clearly indicated that GABA can 
effi ciently bind to the membrane of these cells. The K d  
value obtained (2.740  8 0.721 n M ) indicates affi nities in 
the range as described for instance in brain, other endo-
crine cells or sperm  [51–53] . Nevertheless, the B max  value 
(3.501  8 0.595 fmol/10 6  cells; 28.080  8 4.774 fmol/mg 
protein), was 110–120 times lower than the one described 
in rat cerebellum  [53] and bovine adrenal medulla  [54] , 
60–70 times lower than those reported in rat brain  [51] , 
15–25 times lower than those localized in human sper-
matozoa  [52] and human ovary  [55] , and 4–5 times low-
er than those expressed in rat pituitary  [53] . Thus, results 
obtained indicate that overall only few GABA-binding 
sites exist in TM3 cells, but  they do not allow to judge 
whether all TM3 cells are equally endowed with binding 
sites or whether TM3 cells are heterogeneous in respect 
of their GABA receptor pattern. The detection of binding 
sites and GABA A  receptor subunits alone does also not 
allow to conclude to typical, functional receptors. Al-
though our previous immunohistochemical studies per-
formed in developing and adult testes showed a GABA A  
(  1) subunit protein in Leydig cells  [8, 10] , the full sub-
unit composition in Leydig cells, like in any other periph-
eral endocrine organs, are to our knowledge not known. 
 The points mentioned are of importance in view of the 
observed ‘electrophysiological silence’ of TM3 and adult 
Leydig cells during GABA or isoguvacine treatment. 
These fi ndings contrast markedly to reports on the brain, 
where all GABA A  receptor-mediated effects described ap-
pear to involve Cl –  currents. One possible explanation 
could be related to an assembly pattern of GABA A  recep-
tor subunits different from the one of typical GABA A  re-
ceptors in the brain, which may result in a receptor, but 
not in a functional, typical Cl –  channel. Another possibil-
ity is that the methodologies employed in our studies were 
not sensitive enough to monitor small and fast GABA ef-
fects. In early neurogenesis, GABA A  stimulation was 
shown to depolarize, rather than to hyperpolarize cells, 
and this led to elevated Ca 2+  levels via opening of volt-
age-gated calcium channels  [56–59] . Furthermore the 
second messenger cAMP has been implicated in neural 
and non-neural GABA A  receptor signal transduction  [29–
32] . Importantly, in some cases the depolarizing GABA A  
currents have been reported to be very small (1–4 pA) 
 [23] , a fact that may be related to only few receptors on 
the cell surface. 
 From our binding studies we can also conclude to low 
densities of binding sites corresponding to few GABA A  
receptor subunits on TM3. However, not only did we fail 
to detect Cl –  currents using whole-cell patch-clamp tech-
niques in at least 10 cells tested, but with an array of 
other methods performed in many cells, we also failed 
to measure changes in the cell membrane potential, in-
tracellular Ca 2+  or cAMP levels. Thus, our combined 
results indicate that the GABA A  receptor of Leydig cells 
works through a mechanism different from the neuronal 
GABA A  type. 
 That GABA and the GABA A  agonist are active and 
selectively stimulate TM3 proliferation has been previ-
ously documented  [10] . In the present study we obtained 
further proof of action that taken together indicate that 
GABA can affect a multitude of cellular functions. Thus 
in gene array studies we readily identifi ed several genes 
that were altered. These include, for instance, up- and 
down-regulated genes, associated with cell differentiation 
(e.g. BMP4), cell cycle (cyclin D1, cdk2), other genes as-
sociated with several signalling pathways (p53, Engrail-
ed-1, glycogen synthase) or transcription factors (includ-
ing, c-fos, hsf-1) and the master transcription factor egr-1 
 [60–64] . 
 We focused on egr-1 for several reasons. First, because 
it is not only known to be involved in cell proliferation, 
but also in a plethora of differentiation events. Second, 
because it can be induced by various stimuli and accord-
ingly is ruled by several signalling pathways  [61, 63] . 
Third, because an available specifi c antiserum allows to 
extend the study to the protein level and last, because this 
factor was recently identifi ed to be present in immature 
rodent Leydig cells, but is absent in adult ones, indicated 
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a role during development of Leydig cells  [65] . Our com-
bined results clearly confi rm these data and furthermore, 
egr-1 is seen in the cytoplasm or nucleus of interstitial 
cells in the postnatal testis. Those cells, most of which can 
be readily identifi ed as fetal Leydig cells or mesenchymal 
precursors of adult Leydig cells  [ for details, see  10] , have 
been shown to bear GABA A  receptors and to differentiate 
and to proliferate  [10] . In particular the nuclear location 
of egr-1, i.e. a site where a transcription factor can be 
translocated and then presumably can act, provides at 
least circumstantial evidence that egr-1 is involved in the 
developmental processes in the postnatal testis. In con-
trast, adult Leydig cells in adult testes completely lacked 
egr-1. The precise role of egr-1 in differentiation and or 
proliferation remains to be studied, like the questions 
where in the signalling cascade egr-1 may act, and how it 
may interact with other signalling components. Pilot 
studies in our laboratory provide fi rst hints that mitogen-
activated kinase (erk1/2) could be involved. 
 In the developing brain, GABA has a role of a trophic 
molecule. In immature neurons prior to synapse forma-
tion, GABA is believed to rule cell migration, differentia-
tion and proliferation during neuronal development via 
GABA A -mediated events  [ reviewed in  14] . In developing 
testes, GABA in a similar fashion appears to be involved 
in development of Leydig cells  [10] . Importantly, two in-
dependent reports provide further support for such a 
GABA action via egr-1 to occur in vivo. As mentioned, a 
recent study examining regulated genes during develop-
ment from progenitor to adult stage of rat Leydig cells has 
identifi ed egr-1 in progenitor cells, a result in accordance 
with our current study. However, egr-1 is subsequently 
down-regulated in adult Leydig cells  [65] , again a result 
in line with our present study. Furthermore, GABA is 
present in higher concentration in developing hamster 
testes, with a maximum at day 30, than in adult testes 
 [66] . Thus, GABA and egr-1 are both present in the de-
veloping testis and these independently derived results 
together with our present study imply that they are linked 
and may very well be involved in Leydig cell develop-
ment. 
 In conclusion, our investigation, while failing to show 
expected typical GABA A  receptor-associated signalling 
events known from neurons, reveals fi rst details of a nov-
el action of GABA in TM3 Leydig cells. Whether an un-
usual GABA A  receptor and/or whether low densities of 
GABA receptors are responsible for the observed actions 
of GABA or its apparent absence in TM3 cells remains 
to be fully clarifi ed. 
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